Cantor Fitzgerald Initiates Coverage On Atossa Therapeutics with Overweight Rating, Announces Price Target of $5
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Louise Chen has initiated coverage on Atossa Therapeutics (NASDAQ:ATOS) with an Overweight rating and a price target of $5.
September 08, 2023 | 12:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Atossa Therapeutics has been given an Overweight rating by Cantor Fitzgerald, with a price target of $5.
The Overweight rating from Cantor Fitzgerald indicates a positive outlook for Atossa Therapeutics. The price target of $5 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100